Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $99 from $95 and keeps an Overweight rating on the shares. The firm increased estimates post the Q3 beat.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW: